Value
4.0/10data confidence 83%| Component | Sub-score |
|---|---|
| P/E | 4.1 |
| P/S | 0.0 |
| Fwd P/E | 4.9 |
| PEG | 6.8 |
| Analyst target | 4.0 |
- ▸Forward P/E: 25.6x
- ▸PEG: 1.04
ASND · Why this verdict
Why Ascendis Pharma A/S (ASND) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.8/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue growing at 144% year over year, combined with a growth-plus-profitability score of 158 — described as elite in the assessment — and a noted wide economic moat place this company well ahead of its peer group on expansion and competitive positioning. Quality breakdown | Revenue growth sustains above 50% year over year for at least 2 of the next 4 quarters, confirming this is not a one-period anomaly. | →Stable |
| CounterExtreme growth rates frequently decelerate as the revenue base grows; two of the three fully reported recent quarters missed consensus by wide margins, suggesting execution at this pace is already becoming more difficult. | ||
Despite strong reported earnings, only 24% of net income converts into free cash flow — flagged as an earnings quality red flag — raising questions about the durability of reported profitability and whether capital is being deployed efficiently. Quality breakdown | Free cash flow as a percentage of net income rises above 50% over the next 2 quarters, signaling the conversion gap is closing. | →Stable |
| CounterLow cash conversion in a high-growth phase can reflect heavy reinvestment rather than accounting concerns; if the business continues to scale, operating leverage may improve cash generation organically. | ||
Prior to the most recent quarter's large beat, the two immediately preceding fully reported quarters missed consensus by -124% and -740% respectively, and the average surprise across all reported periods is -145%, signaling that guidance and execution have been highly unreliable. Earnings | EPS surprise exceeds 5% for 2 consecutive quarters after the recent beat, confirming execution has genuinely stabilized. | →Stable |
| CounterThe most recent quarter delivered a very large positive surprise of +429%, which may indicate guidance has been recalibrated conservatively and the historical miss pattern has already ended. | ||
The risk/reward is approximately 2.9-to-1 in the bulls' favor with roughly 20% headroom to the analyst target, but momentum sits just below the preferred threshold — RSI near 38 in a pullback — meaning the market has not yet confirmed the bullish setup. Price targets | Price advances more than 10% from current levels toward the analyst target within 6 months as momentum improves. | →Stable |
| CounterSoft momentum with a mixed technical picture means the stock may remain range-bound or drift lower before recovering, eroding the nominal risk/reward appeal before it can be realized. | ||
Revenue growing at 144% year over year, combined with a growth-plus-profitability score of 158 — described as elite in the assessment — and a noted wide economic moat place this company well ahead of its peer group on expansion and competitive positioning.
→StableQuality breakdown
- Expectation
- Revenue growth sustains above 50% year over year for at least 2 of the next 4 quarters, confirming this is not a one-period anomaly.
CounterExtreme growth rates frequently decelerate as the revenue base grows; two of the three fully reported recent quarters missed consensus by wide margins, suggesting execution at this pace is already becoming more difficult.
Despite strong reported earnings, only 24% of net income converts into free cash flow — flagged as an earnings quality red flag — raising questions about the durability of reported profitability and whether capital is being deployed efficiently.
→StableQuality breakdown
- Expectation
- Free cash flow as a percentage of net income rises above 50% over the next 2 quarters, signaling the conversion gap is closing.
CounterLow cash conversion in a high-growth phase can reflect heavy reinvestment rather than accounting concerns; if the business continues to scale, operating leverage may improve cash generation organically.
Prior to the most recent quarter's large beat, the two immediately preceding fully reported quarters missed consensus by -124% and -740% respectively, and the average surprise across all reported periods is -145%, signaling that guidance and execution have been highly unreliable.
→StableEarnings
- Expectation
- EPS surprise exceeds 5% for 2 consecutive quarters after the recent beat, confirming execution has genuinely stabilized.
CounterThe most recent quarter delivered a very large positive surprise of +429%, which may indicate guidance has been recalibrated conservatively and the historical miss pattern has already ended.
The risk/reward is approximately 2.9-to-1 in the bulls' favor with roughly 20% headroom to the analyst target, but momentum sits just below the preferred threshold — RSI near 38 in a pullback — meaning the market has not yet confirmed the bullish setup.
→StablePrice targets
- Expectation
- Price advances more than 10% from current levels toward the analyst target within 6 months as momentum improves.
CounterSoft momentum with a mixed technical picture means the stock may remain range-bound or drift lower before recovering, eroding the nominal risk/reward appeal before it can be realized.
TrendMatrix Research · core thesis
Engine thesis — one sentence
A high-growth biotech with 144% year-over-year revenue expansion, elite growth-plus-profitability metrics, and wide competitive advantages, but persistent questions about cash conversion quality and a history of large earnings misses temper the case despite a favorable 2.9-to-1 risk/reward and 20% upside to the analyst target.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 4.0 |
| Net margin | 10.0 |
| Current ratio | 4.0 |
| FCF quality | 1.9 |
| Moat | 7.5 |
| Rule of 40 | 9.5 |
| Piotroski F | 4.4 |
- ▸Excellent ROE: 333%
- ▸Strong margins: 57%
- ▸Earnings quality RED FLAG: 24% FCF/NI
- ▸Wide economic moat
Growth
8.4/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 6.9 |
- ▸Strong growth: 144% YoY
Momentum
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.3 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.5 |
- ▸Overbought (RSI 93)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.9 |
| Price target | 6.0 |
| erm sentiment | 5.1 |
Insider
5.6/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 7.2 |
| holder change | 5.2 |
- ▸Modest insider selling — $4,356,609 (0.024% of mkt cap)
Peer rank
5.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.1 |
| quality rank | 9.6 |
| growth rank | 9.0 |
- ▸Superior ROE vs peers
- ▸Best-in-class margins
Technical
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.6 |
| support resistance | 0.1 |
| 52w position | 10.0 |
| gap | 5.0 |
Risk (lower is worse)
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.2 |
| days to cover | 7.2 |
| volatility | 2.8 |
| put call | 8.2 |
| implied vol | 4.2 |
| debt equity | 3.3 |
Catalyst
2.0/10data confidence 75%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 1.1 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 1B/2M
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- MOMENTUM:6.6>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.3=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.26
Upside
-3.9%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The F-path SELL output reflects an overall score of 4.8 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Growth at 8.4) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-0.3=NEGATIVE) reinforce the read. Current asymmetry R:R is -0.26 — supplementary context, not the trigger for this path.
The strongest dimensions are Growth at 8.4, Sentiment at 6.9, and Momentum at 6.6; the weakest are Catalyst at 2.0, Technical at 3.9, and Value at 4.0. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.26 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Elite Growth And Moat
Trip ifRevenue growth falls below 50% year over year for 2 consecutive quarters.
- P2Free Cash Flow Conversion Gap
Trip ifFree cash flow relative to net income rises above 50% for 2 consecutive quarters.
- P3Earnings Track Record Volatile
Trip ifEPS surprise exceeds 5% for 2 consecutive quarters, confirming execution has stabilized.
- P4Favorable Risk Reward Soft Momentum
Trip ifRSI rises above 55 and price advances more than 12% from the current level of $223 within 3 months.